Vasogen: Celcade cuts death risk in some heart failure patients

By E. Janene Geiss

Philadelphia, Sept. 5 - Vasogen Inc. said Tuesday that new data from the 2,400-patient Acclaim trial in chronic heart failure showed that in a major combined subgroup of New York Heart Association class III/IV patients with no prior history of heart attack and all class II patients, together comprising more than 50% of the study population, Vasogen's Celacade technology reduced the risk of death and cardiovascular hospitalization by 31%.

Celacade also was shown to be safe and well-tolerated, according to results presented Tuesday at the World Congress of Cardiology meeting in Barcelona.

The results provide evidence that Celacade significantly reduces the risk of death and cardiovascular hospitalization in an important group of heart failure patients, the Mississuaga, Ont., pharmaceutical company said in a news release.

These results provide a strong basis for targeting Celacade's novel anti-inflammatory mechanism in a large and well-defined patient population, officials said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.